

REMARKS

Claims 1-10, 13 and 15-22 are pending in this application. In this second preliminary amendment, the compound according to formula (I) has been amended to more clearly define its claimed features, both in the specification and the claims. The structure of the compound of formula (I) is incorrect as it depicts a penta-valent carbon atom on the phenyl ring on the right hand side of the molecule. Such a mistake was an inadvertent error without deceptive intent. The correct structure would be obvious from the structure of the intermediates of formulae (II), (III), (V), (VII), (VIII) and (XI) (see page 19, pages 23 to 27 and claim 15), and the examples. In particular, on page 19 of the description it is stated that a compound of formula (I) may be obtained by deprotection of a protected intermediate of formula (II), which has the correct structure and only differs from a compound of formula (I) by the protecting group (P¹) on the oxygen at the left hand side of the molecule. It would be immediately evident that nothing else would have been intended than what is offered as the correction. Thus, no new matter is entered into the specification by virtue of this amendment.

Entry of this amendment is respectfully requested.

Respectfully submitted,

/Robert J. Smith/
Robert J. Smith
Attorney for Applicant
Registration No. 40,820

Date: March 27, 2007
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-9616
Facsimile: 919-483-7988